tm logo

Monitor this mark

View On USPTO

RETASQI
Dead/Cancelled
IR CANCELLED; US REGISTRATION CANCELLED

on 01 Mar 2023

Last Applicant/ Owned by

IPSEN PHARMA S.A.S

F-92100 BOULOGNE BILLANCOURT

FR

Serial Number

79128029 filed on 01st Mar 2013

Registration Number

4473126 registered on 28th Jan 2014

in the Principal Register

Correspondent Address

William S. Frommer, Esq.

William S. Frommer, Esq.

745 FIFTH AVENUE, 10th Floor

NEW YORK NY 10151

Filing Basis

1. filing basis filed as 66 a

Disclaimer

NO DATA

RETASQI

Pharmaceutical preparations for use in oncology, endocrinology, neurology, hematology, gastroenterology, urology and for cardiovascular and cognitive disorders

Classification Information

Class [005]
Pharmaceutical Products

Pharmaceutical preparations for use in oncology, endocrinology, neurology, hematology, gastroenterology, urology and for cardiovascular and cognitive disorders

Mark Details

Serial Number

No 79128029

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 452301-8094

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

Yes

66A Current

Yes

Current Basis

No

No Basis

No

Legal History

Show more

Status DateAction Taken
24th Sep 2023DEATH OF INTERNATIONAL REGISTRATION
24th Sep 2023NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
06th Mar 2022TOTAL INVALIDATION PROCESSED BY THE IB
04th Feb 2022INVALIDATION PROCESSED
04th Feb 2022TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
26th Oct 2021TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
26th Feb 2021CANCELLED SECTION 71
18th Jun 2020REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED
15th May 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
15th May 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED